Pds biotech to participate at b. riley securities 4th annual oncology conference

Princeton, n.j., jan. 16, 2024 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (“pds biotech” or “the company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the company's proprietary t cell activating platforms, today announced that frank bedu-addo, phd, president and chief executive officer of pds biotech, will participate in a fireside chat at the b. riley securities 4th annual oncology conference taking place virtually on thursday, january 18, 2024, at 10:00 am est. details are as follows:
PDSB Ratings Summary
PDSB Quant Ranking